Agio RUS Llc Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: Agio RUS Llc Pharmaceutical Import Records from India — 8 Products, $5.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Agio RUS Llc — Pharmaceutical Importer Profile (2026) | 8 Products, $5.2M Trade | TransData Nexus

Agio RUS Llc

Pharmaceutical Importer · Russia · Respiratory & OTC Focus · $5.2M Total Trade · DGFT Verified

Agio RUS Llc is a pharmaceutical importer based in Russia with a total trade value of $5.2M across 8 products in 5 therapeutic categories. Based on 276 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Agio RUS Llc sources from 1 verified Indian supplier, with Agio Pharmaceuticals Limited accounting for 100.0% of imports.

Agio RUS Llc — Import Portfolio & Supplier Network

Agio RUS Llc import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Agio RUS Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Agio Pharmaceuticals Limited	$19.6M	778	100.0%

Agio RUS Llc sources from 1 verified Indian supplier across 204 distinct formulations. The sourcing is highly concentrated — Agio Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Agio RUS Llc Import?

Formulation	Value	Ships
Agisept antiseptic lozenges / tablets	$2.1M	43
Agisept antiseptic lozenges / tablets -honey & lemon (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges)	$1.3M	40
Agisept antiseptic lozenges / tablets -menthol & eucalyptus (2,4 dichlorobenzylalcohol and amylmetacresol lozenges)	$805.4K	24
Agisept antiseptic lozenges / tablets -classical (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges)	$717.1K	19
Agisept antiseptic lozenges / tablets -honey & lemon (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges	$576.3K	24
Kofasma syrup 200 ML (bromhexine + guaifenesin + salbutamol syrup)	$546.4K	23
Agisept antiseptic lozenges / tablets -classical (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges	$434.3K	18
Aginim gel (nimesulide gel 1 % w/w)	$425.4K	15
Agisept antiseptic lozenges / tablets -honey & lemon 2,4 dichlorobenzyl alcohol and amylmetacresol	$400.0K	8
Agisept antiseptic lozenges / tablets -orange (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges)	$394.6K	10
Agisept antiseptic lozenges / tablets -lemon (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges)	$390.3K	8
Agisept antiseptic lozenges / tablets -honey & lemon (24 dichlorobenzyl alcohol and amylmetacresol lozenges	$367.9K	15
Agisept antiseptic lozenges / tablets -pineapple (2,4 dichlorobenzyl alcohol and amylmetacresol lozenges)	$361.4K	9
Agisept antiseptic lozenges / tablets -classical 24 dichlorobenzyl alcohol and amylmetacresol	$350.0K	7
Agisept antiseptic lozenges / tablets -menthol & eucalyptus 24 dichlorobenzylalcohol and amylmetacresol	$300.0K	6

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Phenylephrine	Respiratory & OTC	$1.7M	96	2.0%	11
2	Guaifenesin	Respiratory & OTC	$837.4K	33	3.1%	5
3	Bromhexine	Respiratory & OTC	$811.2K	34	5.0%	3
4	Clotrimazole	Antifungals	$647.8K	46	0.7%	17
5	Gentamicin	Antibiotics	$439.6K	30	0.9%	14
6	Chlorpheniramine	Antihistamines & Allergy	$261.0K	13	0.6%	17
7	Salicylic	Combination Drugs	$237.6K	14	1.4%	12
8	Miconazole	Antifungals	$210.2K	10	1.1%	13

Agio RUS Llc imports 8 pharmaceutical products across 5 categories into Russia totaling $5.2M.

Agio RUS Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Agio RUS Llc is a pharmaceutical importer based in Moscow, Russia, specializing in the procurement of finished pharmaceutical formulations. Established to meet the growing demand for diverse therapeutic products, Agio RUS Llc plays a pivotal role in Russia's pharmaceutical distribution network. The company operates as a primary wholesaler, sourcing a wide array of pharmaceutical products from international suppliers to cater to the needs of the Russian market.

The company's headquarters are located at 115230, Moscow, Kashirskoye Shosse, 3 Building 2/4 Room 5, Moscow, Russia. Agio RUS Llc's parent company, Agio Pharmaceuticals Limited, is a prominent pharmaceutical manufacturer based in India. This affiliation enables Agio RUS Llc to leverage a robust supply chain, ensuring a steady influx of high-quality pharmaceutical products into Russia.

2Distribution Network

Agio RUS Llc's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Russia. While specific warehouse locations are not publicly disclosed, the company's logistics capabilities are evident through its extensive import activities. Between 2022 and 2026, Agio RUS Llc facilitated 276 shipments from India, underscoring its capacity to manage substantial volumes of pharmaceutical imports. The primary port of entry for these shipments is Novorossiysk, a major port on the Black Sea, which serves as a critical hub for the importation of goods into Russia.

The company's geographic coverage spans the entirety of Russia, ensuring that pharmaceutical products reach both urban centers and remote regions. This extensive reach is facilitated by a combination of direct distribution channels and partnerships with local wholesalers and retailers, enabling Agio RUS Llc to effectively serve the diverse needs of the Russian pharmaceutical market.

3Industry Role

In Russia's pharmaceutical supply chain, Agio RUS Llc functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, particularly from India, the company ensures a consistent supply of essential medications to the Russian market. This role is crucial in a market where domestic production may not fully meet the demand for certain pharmaceutical products. Agio RUS Llc's operations bridge the gap between international manufacturers and Russian healthcare providers, facilitating the availability of a wide range of therapeutic options.

The company's focus on importing finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a strategic decision to streamline the supply chain and reduce the complexities associated with local manufacturing. This approach allows Agio RUS Llc to concentrate on distribution and logistics, ensuring timely delivery of ready-to-use pharmaceutical products to the Russian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Agio RUS Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Agio RUS Llc exhibits a high degree of sourcing concentration, with a single supplier—Agio Pharmaceuticals Limited—accounting for the entirety of its pharmaceutical imports. Between 2022 and 2026, the company imported products worth $5.2 million USD across 276 shipments, all sourced from Agio Pharmaceuticals Limited.

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a sole supplier relationship can lead to streamlined operations, consistent product quality, and favorable terms due to the volume of business conducted. However, this concentration also exposes Agio RUS Llc to risks associated with supply chain disruptions, such as production delays, geopolitical issues, or regulatory changes affecting the supplier.

The stability of this relationship is crucial. The consistent volume of imports over the years suggests a strong and reliable partnership between Agio RUS Llc and Agio Pharmaceuticals Limited. Nonetheless, it is imperative for Agio RUS Llc to monitor this dependency and consider diversifying its supplier base to mitigate potential risks and ensure a resilient supply chain.

2Supply Chain Resilience

Agio RUS Llc's supply chain resilience is closely tied to its exclusive partnership with Agio Pharmaceuticals Limited. This singular supplier relationship simplifies logistics and quality control processes but also means that any disruption at the supplier's end can significantly impact Agio RUS Llc's operations.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

The regulation of pharmaceutical imports into Russia is governed by the Federal Service on Surveillance in Healthcare, known as Roszdravnadzor. This federal executive body is responsible for ensuring the safety, quality, and efficacy of medical products circulating within the Russian Federation.

Key legislation governing pharmaceutical imports includes Federal Law No. 61-FZ "On the Circulation of Medicinal Products," which outlines the procedures for the importation, registration, and distribution of medicinal products in Russia. This law establishes the framework for ensuring that imported pharmaceuticals meet the necessary standards for public health and safety.

The marketing authorization pathway for Indian generics involves obtaining a registration certificate from Roszdravnadzor. This process requires the submission of comprehensive documentation, including evidence of the product's quality, safety, and efficacy, as well as compliance with Russian regulatory standards. The registration process is designed to ensure that all medicinal products, including generics, meet the stringent requirements set forth by Russian authorities.

2Import Licensing & GMP

Import licensing for pharmaceutical products in Russia is a two-step process. First, permits are issued by Roszdravnadzor, which oversees the safety and quality of medical products. Following the issuance of permits, licenses are granted by the Ministry of Industry and Trade, authorizing the importation and distribution of the pharmaceutical products within Russia.

Frequently Asked Questions — Agio RUS Llc

What products does Agio RUS Llc import from India?

Agio RUS Llc imports 8 pharmaceutical products across 5 categories. Top imports: Phenylephrine ($1.7M), Guaifenesin ($837.4K), Bromhexine ($811.2K), Clotrimazole ($647.8K), Gentamicin ($439.6K).

Who supplies pharmaceuticals to Agio RUS Llc from India?

Agio RUS Llc sources from 1 verified Indian suppliers. The primary supplier is Agio Pharmaceuticals Limited (100.0% of imports, $19.6M).

What is Agio RUS Llc's total pharmaceutical import value?

Agio RUS Llc's total pharmaceutical import value from India is $5.2M, based on 276 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Agio RUS Llc focus on?

Agio RUS Llc imports across 5 categories. The largest: Respiratory & OTC (65.2%), Antifungals (16.6%), Antibiotics (8.5%).

Get Full Agio RUS Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.